M20 Genomics

What M20 Genomics does

M20 Genomics is a private life science technology company founded in February 2021 and headquartered in Singapore (with operations traceable to Hangzhou, China) that develops a proprietary single-cell and spatial transcriptomics platform built on its M20 Seq random-primer chemistry. Unlike poly(A)-tail-based methods, M20 Seq captures full-length transcriptomes, works across both eukaryotic and prokaryotic cells, and is compatible with FFPE, frozen, and fresh samples, enabling detection of mRNA, non-coding RNAs, alternative splicing, gene fusions, copy number variations, and gene mutations at single-cell resolution. The flagship VITA Single-Cell Full-Length Transcriptome Sequencing Platform is a three-component stack consisting of the VITAcruizer partitioning instrument, VITApilote library preparation kits (across FFPE, frozen, bacterial, and gut microbiome workflows), and VITAseer bioinformatics software, complemented by M20 Spatial technology for spatial transcriptomics.

The company generates revenue through capital equipment sales (VITAcruizer), consumable reagent kits (VITApilote and the VITA GutMicrobiome/OralMicrobiome/SoilMicrobiome specialty kits), software subscriptions (VITAseer with VITAbasic/VITAprok/VITAeuk modules), and field-services revenue (installation, training, technical support). Go-to-market is enterprise field sales with consultation-based, quote-only pricing directed at academic research institutions, universities, clinical research centers, pharmaceutical/biotech companies, and microbiome researchers in the US, Europe, and Asia; distribution is increasingly augmented through a service-provider network including UCLA TCGB, Complete Omics (Baltimore), AmpSeq (Gaithersburg), and Oxford MEStar.

Target customer segments include basic research (cancer, neurobiology, immunology, developmental biology), clinical research (oncology, reproductive medicine, infectious disease), pharmaceutical and drug development (target screening, MOA studies, vaccine development), antimicrobial resistance research, and microbiome research. The company has been venture-backed by Sequoia Capital, Qiming Venture Partners, Nest. Bio Capital, Taiyu Investments, and QiZhen Future Healthcare Fund across angel and pre-A rounds in 2021-2022 and continues to add distribution and product capabilities globally.

Name

M20 Genomics

Legal name

M20 Genomics

Website

https://m20genomics.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

M20 Genomics is a private life science technology company developing a proprietary random-primer-based single-cell and spatial full-length transcriptome sequencing platform (VITA) for academic research institutions, clinical researchers, pharmaceutical companies, and microbiome laboratories across the US, Europe, and Asia.

Ownership category

akta.pro rank

Product category

Single-Cell Sequencing Instruments and Reagents

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)

Keywords

• Single-cell sequencing
• Spatial transcriptomics
• Life science tools
• Library preparation reagents
• Bioinformatics software

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. VITA Platform Hardware Sales: Sale of VITA Single-Cell Full-Length Transcriptome Sequencing Platform including VITAcruizer Single-Cell Partitioning System instrument.
2. Reagent Kits: Sale of VITApilote Library Preparation Kits for different sample types including FFPE Samples, Frozen Samples, Single-Bacterium Transcriptome Kit, and GutMicrobiome kits.
3. VITAseer Software License: Bioinformatics software for processing single-cell transcriptome data with modules for eukaryotic and prokaryotic analysis.
4. VITA Fixed RNA Reagent: RNA fixation reagent for direct fixation of tissue samples enabling flexible single-cell research and field collections.
5. Service Provision: Full transcriptome profiling services at customer sites including installation, training, and technical support.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

M20 Genomics develops and sells the VITA Single-Cell Full-Length Transcriptome Sequencing Platform, powered by its proprietary M20 Seq random primer technology. The platform comprises the VITAcruizer partitioning instrument, VITApilote library preparation kits, and VITAseer bioinformatics software, and is complemented by the M20 Spatial solution for spatial transcriptomics. The offering enables full-length, 5'-3' single-cell RNA sequencing across diverse sample types (FFPE, frozen, fresh, microbial) and species (eukaryotes and prokaryotes).

Product overview

M20 Genomics offers a unified platform-plus-modules architecture centered on its proprietary M20 Seq random primer technology. The core VITA Single-Cell Full-Length Transcriptome Sequencing Platform comprises three integrated components: VITAcruizer (Single-Cell Partitioning System instrument), VITApilote (Library Preparation Kits), and VITAseer (Bioinformatics Software). This platform is complemented by M20 Spatial for spatial transcriptomics. The product portfolio includes specialized applications for different sample types (FFPE, Frozen, Cultured Bacterial, Gut Microbiota) and software modules (VITAbasic, VITAprok, VITAeuk, VITA CytBase). Recent additions include VITAscout (AI-assisted QC), VITA Fixed RNA Reagent, and specialized microbiome solutions (VITA GutMicrobiome, VITA OralMicrobiome, VITA SoilMicrobiome). The technology is designed for compatibility with Illumina and MGI sequencing platforms.

Differentiator

Problem solved

Functional benefit

Brands

• M20 Seq: Proprietary random primer technology for single-cell RNA sequencing enabling full transcriptome coverage.
• M20 Spatial
• VITA
• VITAcruizer
• VITApilote
• VITAseer
• VITAscout
• VITAprok
• VITAeuk
• VITAbasic
• VITA Fixed RNA
• VITA OralMicrobiome
• VITA SoilMicrobiome
• MscRNA-seq

Products and services

• VITA Single-Cell Full-Length Transcriptome Sequencing Platform Flagship integrated platform for comprehensive single-cell transcriptome analysis across diverse sample types and species with full-length 5'-3' transcript coverage. Includes VITAcruizer instrument, VITApilote reagent kits, and VITAseer bioinformatics software.
• VITAcruizer Single-Cell Partitioning System Standalone instrument that performs single-cell partition, capture, and barcoding for both eukaryotic and prokaryotic cells across fresh, frozen, and FFPE tissue samples. Supports standard (1,000-20,000 cells) and ultra-high throughput (millions of cells) workflows.
• VITApilote Library Preparation Kits Series of optimized reagent kits for library preparation from diverse sample types, including variants for FFPE samples, frozen samples, single-bacterium transcriptome, and gut microbiome.
• VITAseer Bioinformatics Software Bioinformatics software for processing single-cell transcriptome data, including barcode identification, QC, alignment, gene expression matrix generation, clustering, and marker gene analysis with downstream modules for eukaryotic and prokaryotic analysis.
• M20 Spatial Transcriptome Solution Spatial full-length transcriptome technology with universal sample compatibility (FFPE, frozen, fresh). Achieves spatial resolution down to 15 µm and detects over 5,000 genes per 50 µm spot.
• VITA Fixed RNA Reagent RNA fixation reagent for direct fixation of tissue samples, preserving cellular information and enabling flexible sample handling for field collections when immediate processing is not feasible.
• Single-Cell Transcriptome for FFPE Samples High-throughput single-cell solution for detecting gene expression in formalin-fixed paraffin-embedded samples. Integrates VITApilote kit for FFPE, VITAcruizer system, and VITAseer software to analyze 1,000-20,000 cells per sample with comprehensive mRNA and non-coding RNA analysis.
• Single-Cell Transcriptome for Frozen Samples Comprehensive solution for unbiased full-length transcriptome profiling of eukaryotic cryopreserved samples, including mRNA, non-coding RNA, and alternative splicing analysis from 1,000-20,000 cells per sample.
• Single-Cell Transcriptome for Cultured Bacterial Samples MscRNA-seq high-throughput single-species single-bacterium transcriptome solution that analyzes 1,000-20,000 bacteria per sample for investigating gene expression, drug resistance mechanisms, and host-bacteria interactions.
• VITA GutMicrobiome Single-bacterium transcriptomic solution for gut microbiome research, profiling 1,000-20,000 bacteria per sample to study functional and phenotypic heterogeneity within the gut microbiome for live biotherapeutic products and fecal microbiota transplantation research.
• VITA OralMicrobiome Single-cell transcriptomics solution for oral microbiome research, enabling single-bacterium resolution transcriptional profiling of oral microbial communities and disease-associated microbial programs.
• VITA SoilMicrobiome Single-cell transcriptomics solution for soil microbiome research, addressing the technical challenges of analyzing complex soil microbial communities with high biodiversity and density.

Quantifiable outcome

• Over 5,000 genes detected per 50 µm spot in spatial transcriptomics
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature8 records

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

• Complete OmicsflagshipStrategic or Co-development Partner · 1 August 2024Strategic partnership to advance single-cell multi-omics for precision medicine. Partnership integrates M20 Genomics' single-cell and spatial transcriptomics platforms with Complete Omics' proteomics and metabolomics technologies. Key aspect is the establishment of a joint laboratory in Baltimore, Maryland, close to Johns Hopkins University, serving as a hub for developing and optimizing integrated single-cell multi-omics assays.
• University Hospital HeidelbergcoreStrategic or Co-development PartnerEuropean research collaboration with installation of VITA Single-Cell Full-Length Transcriptome Platform. Platform serves as a central hub for collaborative research in Europe, providing single-cell sequencing services to the hospital and neighboring institutions. Plans to extend services to additional clients across the continent.
• Duke University School of MedicinecoreStrategic or Co-development PartnerInstallation of VITA platform in collaboration labs at Duke University School of Medicine. Strategic partnership advances scientific resources enabling precise transcriptomic profiling at the single-cell level with detailed insights into cellular mechanisms.
• UCLA Technology Center for Genomics & Bioinformatics (TCGB)coreStrategic or Co-development PartnerInstallation of VITA Platform at TCGB enabling transcriptomic profiling in various sample types and species with single-cell resolution. Collaboration enhances the spectrum of tools available to local research teams.
• AmpSeq, LLCminorImplementation/ SI/ Consulting PartnerService provider located in Gaithersburg, MD, USA providing sequencing services. Contact: +1 240-654-6236, [email protected].
• Oxford MEStar LtdminorImplementation/ SI/ Consulting PartnerService provider located at Begbroke Science Park, Oxford, UK. Contact: +44 1865 309699, [email protected].

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Illumina: Dominant next-generation sequencing platform provider (NovaSeq, NextSeq) and parent of single-cell assets acquired from 1Cell Bio. Adjacent incumbent whose installed base M20 depends on for downstream sequencing and which has signaled ambition in single-cell.
• Bruker (NanoString CosMx / GeoMx): Acquired NanoString in 2024, owning CosMx SMI (single-cell spatial) and GeoMx (spatial profiling) platforms. Established spatial transcriptomics competitor to M20 Spatial with deeper pharma channels.

Direct peers

• 10x Genomics: Leading single-cell sequencing platform (Chromium) and spatial platform (Visium, Xenium). Directly competes with M20 in single-cell transcriptomics workflows serving the same academic and translational research customers.
• BD Biosciences (BD Rhapsody): Offers the Rhapsody single-cell sequencing platform competing head-to-head with VITA in academic core facilities and translational research labs, with established commercial channels and instrument placements.
• Singleron Biotechnologies: China-based single-cell sequencing company offering the Singleron Matrix and AccuraSCK platforms. Closest head-to-head peer given parallel China origin, similar academic customer base, and overlapping transcriptomics offerings.
• Bio-Rad (ddSEQ): Offers the ddSEQ single-cell sequencing solution as part of its droplet-based genomics portfolio. Competes directly for academic core-facility instrument placements with an established global sales and support network.

Emerging players

• Element Biosciences: Sequencing platform company (AVITI) challenging Illumina on cost and flexibility. Relevant peer as M20's libraries are compatible with multiple sequencers and Element's adoption could expand M20's downstream-sequencer footprint.
• Fluent BioSciences: PIP-seq-based single-cell sequencing technology without dedicated instruments. Overlaps with M20's mission of making single-cell accessible to a broader research base, including challenging sample types.
• Vizgen: Spatial transcriptomics company offering MERFISH-based single-cell spatial gene expression. Competes with M20 Spatial in the fast-growing spatial biology market, particularly in neuroscience and oncology.
• Parse Biosciences: Single-cell sequencing company offering Evercode with a combinatorial barcoding workflow that avoids dedicated instrument purchases. Competes with VITA in scalable eukaryotic single-cell workflows, especially for customers without capital budget for new instruments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/m20genomics
• LinkedInlinkedin.com/company/m20-genomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about M20 Genomics